{"id":"W4405215161","doi":"10.1016/j.eclinm.2024.102991","title":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; BC Cancer Agency; Cancer Care Ontario; McGill University; McGill University Health Centre; Juravinski Cancer Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; BC Studies; Princess Margaret Cancer Centre; Centre Hospitalier de l’Université de Montréal; Hamilton Health Sciences","funders":"Canadian Cancer Society Research Institute; Canadian Cancer Society; AstraZeneca","keywords":"Durvalumab; Medicine; Tremelimumab; Open label; Cancer; Internal medicine; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007320672,0.0003480898,0.0009320351,0.0002261879,0.0001083349,0.00004751875,0.0002170146,0.0001839355,0.0005901821],"category_scores_gemma":[0.0002614991,0.000235196,0.00007443115,0.0006685512,0.0002675348,0.0002227632,0.0001420438,0.0005431778,0.000009750953],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001899651,"about_ca_system_score_gemma":0.0005458199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002969429,"about_ca_topic_score_gemma":0.0003061647,"domain_scores_codex":[0.9972351,0.00008034735,0.0009617677,0.0007977242,0.00048434,0.0004407327],"domain_scores_gemma":[0.9986992,0.0002738918,0.0001555868,0.0004652221,0.0001241364,0.0002819005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4838507,0.007798967,0.01609993,0.0002332333,0.0004195489,0.0002014468,0.0006225323,8.017631e-7,0.0002477597,0.000005453881,0.004155529,0.486364],"study_design_scores_gemma":[0.9106899,0.0211014,0.03784864,0.003576398,0.0003373915,0.000009188871,0.0001659772,0.001620614,0.00006235451,0.00001171869,0.02421241,0.0003640038],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838654,0.004783312,0.00004454435,0.006493486,0.001183972,0.003189632,0.0000934436,0.00008042877,0.0002657737],"genre_scores_gemma":[0.9919726,0.002054844,0.001090142,0.002258425,0.0004815705,0.0001799538,0.0001548173,0.00007138323,0.001736268],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.486,"threshold_uncertainty_score":0.9591016,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06434953328348646,"score_gpt":0.4123380692197086,"score_spread":0.3479885359362221,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}